Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
The current status of CLL treatment and how clinical practice will change
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
Are prognostic factors the key to precision medicine in CLL?
MRD negativity and its role as a predictor for CLL patient responses